News
GLTO
5.62
-3.85%
-0.23
Weekly Report: what happened at GLTO last week (1111-1115)?
Weekly Report · 5d ago
Weekly Report: what happened at GLTO last week (1104-1108)?
Weekly Report · 11/11 09:04
Weekly Report: what happened at GLTO last week (1028-1101)?
Weekly Report · 11/04 09:04
Galecto, Inc.’s Strategic Shift to Oncology and Liver Diseases: Navigating Risks and Opportunities
NASDAQ · 11/02 06:01
Galecto, Inc. Announces Strategic Shift and Financial Overview
TipRanks · 11/02 04:13
Galecto Inc reports results for the quarter ended in September 30 - Earnings Summary
Reuters · 11/02 02:12
Based on the provided financial report, the title of the article is: "Form 10-Q: Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934" This title indicates that the report is a quarterly report filed by the company with the Securities and Exchange Commission (SEC) under the Securities Exchange Act of 1934.
Press release · 11/01 20:50
Galecto reports Q3 results
Seeking Alpha · 11/01 15:11
Galecto Q3 EPS $(3.39) Beats $(4.10) Estimate
Benzinga · 11/01 12:37
Galecto reports Q3 EPS ($3.39) vs ($7.50)
TipRanks · 11/01 12:36
Weekly Report: what happened at GLTO last week (1021-1025)?
Weekly Report · 10/28 09:04
Weekly Report: what happened at GLTO last week (1014-1018)?
Weekly Report · 10/21 09:04
Galecto Is Maintained at Outperform by Oppenheimer
Dow Jones · 10/17 13:32
Galecto Price Target Raised to $10.00/Share From $9.00 by Oppenheimer
Dow Jones · 10/17 13:32
Oppenheimer Maintains Outperform on Galecto, Raises Price Target to $10
Benzinga · 10/17 13:21
GALECTO INC <GLTO.O>: OPPENHEIMER RAISES TARGET PRICE TO $10 FROM $9
Reuters · 10/17 12:15
Galecto price target raised to $10 from $9 at Oppenheimer
TipRanks · 10/17 12:15
Oppenheimer Sticks to Its Buy Rating for Galecto (GLTO)
TipRanks · 10/17 12:07
More
Webull provides a variety of real-time GLTO stock news. You can receive the latest news about Galecto Inc. through multiple platforms. This information may help you make smarter investment decisions.
About GLTO
Galecto, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel treatments for cancer and liver diseases. The Company’s pipeline consists small molecule drug candidates that target cancer and fibrosis signaling pathways, including an orally active galectin-3 inhibitor (GB1211) for the treatment of liver cirrhosis; an orally active galectin-3 inhibitor (GB1211) in combination with a checkpoint inhibitor for various oncology indications; and a preclinical dual inhibitor of ENL-YEATS and FLT3 (BRM-1420) for multiple genetic subsets of acute myeloid leukemia (AML). The GB1211, is also being developed for the treatment of non-small cell lung cancer (NSCLC), melanoma, head and neck squamous cell carcinoma (HNSCC), and decompensated cirrhosis.